Want to see FR:ALSPW full AI Analyst Report?
Spineway SA (ALSPW) AI Stock Analysis
Spineway SA
(Paris:ALSPW)
The score is held back primarily by continued losses and lack of sustainably positive free cash flow despite improving revenue/margins and a relatively strong, low-leverage balance sheet. Technically, the stock is in a weak trend below major moving averages, while valuation is constrained by negative earnings and no dividend support.
Spineway SA (ALSPW) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 3.09M
- Dividend Yield
- ―
- Average Volume (3M)
- 153.74K
- Price to Earnings (P/E)
- -1.3
- Beta (1Y)
- 0.28
- Revenue Growth
- 14.51%
- EPS Growth
- 59.71%
- Country
- France
- Employees
- 43
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Specialties
Spineway SA Business Overview & Revenue Model
Company Description
Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion pro...
How the Company Makes Money
Spineway generates revenue primarily by selling spinal surgery products to healthcare providers and/or distributors, including spinal implants (devices implanted in the patient) and the associated surgical instruments and systems required to implant...
Spineway SA Financial Statement Overview
Summary
Revenue growth and margin recovery are improving the operating profile, and operating cash flow turned positive in 2025. However, the company remains loss-making with negative net margins and lacks sustainably positive free cash flow, keeping overall financial quality only mid-range despite a low-leverage balance sheet.
Income Statement
34NegativeBalance Sheet
74PositiveCash Flow
42Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.43M | 12.43M | 11.95M | 10.52M | 7.43M | 4.29M |
| Gross Profit | 3.27M | 3.27M | 3.36M | 1.63M | 237.00K | -1.45M |
| EBITDA | -1.12M | -1.12M | -5.35M | -4.79M | -2.76M | -1.04M |
| Net Income | -2.24M | -2.24M | -3.86M | -6.51M | -3.14M | -1.58M |
Balance Sheet | ||||||
| Total Assets | 29.46M | 29.46M | 30.41M | 26.31M | 27.70M | 25.57M |
| Cash, Cash Equivalents and Short-Term Investments | 3.50M | 3.50M | 4.52M | 1.80M | 5.50M | 13.89M |
| Total Debt | 1.53M | 1.53M | 1.82M | 2.60M | 1.43M | 2.40M |
| Total Liabilities | 6.40M | 6.40M | 6.17M | 7.26M | 5.69M | 4.69M |
| Stockholders Equity | 23.06M | 23.06M | 24.24M | 19.05M | 22.00M | 20.88M |
Cash Flow | ||||||
| Free Cash Flow | 538.00K | 0 | -3.27M | -7.29M | -13.89M | -2.88M |
| Operating Cash Flow | 424.00K | 424.00K | -3.27M | -5.83M | -1.62M | -1.79M |
| Investing Cash Flow | -1.17M | -1.17M | -1.01M | -1.39M | -10.20M | -578.00K |
| Financing Cash Flow | -269.00K | -269.00K | 7.01M | 3.49M | 3.72M | 11.45M |
Spineway SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSPW, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 33.79 is Neutral, neither overbought nor oversold. The STOCH value of 11.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALSPW.
Spineway SA Peers Comparison
Overall Rating
FR:CVX55Neutral- FR:ALSPW49Neutral
FR:ALIMP45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FR:CVX | 55Neutral | EUR 352.20M | -8.71 | -120.57% | ― | -100.00% | -72.33% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FR:ALSPW | 49Neutral | EUR 3.09M | -1.31 | -10.07% | ― | 14.51% | 59.71% |
| FR:ALIMP | 45Neutral | EUR 21.40M | -5.18 | 671.47% | ― | 24.35% | 15.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALSPW | Spineway SA | 0.09 | -0.07 | -44.59% | |
| FR:ALSAF | Safe Orthopaedics | 0.64 | -1.76 | -73.33% | |
| FR:CVX | Affluent Medical SA | 5.66 | 4.02 | 244.07% | |
| FR:ALIMP | Implanet SA | 0.15 | -0.11 | -41.96% |
Spineway SA Corporate Events
Spineway Nine‑Month Revenue Slips as Supply Issues Hit Growth; Names Deputy CEO
Spineway reported nine‑month 2026 revenue of €8.0 million, down 7% year‑on‑year, with quarterly sales volatility driven by supply chain issues despite underlying demand. Q3 revenue fell 25% to €2.3 million, while France...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 17, 2026